Skip to main content
SpringerLink
Log in
Book cover

Musculoskeletal Cancer Surgery pp 75–84Cite as

Isolated Limb Perfusion in the Treatment of Advanced Soft-tissue Sarcomas

  • Chapter

  • 933 Accesses

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   189.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   299.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Creech O, Krementz ET, Ryan RF et al. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg. 1958;148:616–31.

    PubMed  Google Scholar 

  2. Stehlin JS. Hyperthermic perfusion with chemotherapy for cancers of the extremities. Surg Gynecol Obstet. 1969;129:305–8.

    PubMed  Google Scholar 

  3. Lienard D, Ewaienko P, Delmotti JJ et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol. 1992; 10:52–60.

    CAS  PubMed  Google Scholar 

  4. Wieberdink J, Benckhuysen C, Braat RP et al. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur Cancer Clin Oncol. 1982;18:905–10.

    CAS  Google Scholar 

  5. Sorkin P, Abu-Abid S, Lev D et al. Systemic leakage and side effects of tumor necrosis factor administered via isolated limb perfusion can be manipulated by flow rate adjustment. Arch Surg. 1995;130:1079–84.

    CAS  PubMed  Google Scholar 

  6. Barker WC, Andrich MP, Alexander HR et al. Continuous intraoperative external monitoring of perfusate leak using I-131 human serum albumin during isolated perfusion of the liver and limbs. Eur J Nucl Med. 1995;22:1242–8.

    Article  CAS  PubMed  Google Scholar 

  7. Thom AK, Alexander HR, Andrich MP et al. Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion (ILP) with high-dose TNF, interferon-gamma and melphalan. J Clin Oncol. 1995;13:264–73.

    CAS  PubMed  Google Scholar 

  8. Eggermont AMM, Schraffordt-Koops H, Klausner JM et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft-tissue extremity sarcomas: the cumulative multicenter European experience. Ann Surg. 1996;224:756–65.

    Article  CAS  PubMed  Google Scholar 

  9. Briele HA, Dyuric M, Jung DT et al. Pharmacokinetics of melphalan in clinical isolation perfusion of the extremities. Cancer Res. 1985;45:1885–9.

    CAS  PubMed  Google Scholar 

  10. Ghussen F, Kruger I, Groth W et al. The role of hyperthermic cytostatic perfusion in the treatment of extremity melanoma. Cancer. 1988;61:654–9.

    CAS  PubMed  Google Scholar 

  11. Hafstrom L, Rudenstam CM, Blomquist E et al. Regional hyperthermic perfusion with melphalan after surgery for recurrent melanoma of the extremities. J Clin Oncol. 1991;9:2091–4.

    CAS  PubMed  Google Scholar 

  12. Lienard D, Eggermont AM, Kroon BBR et al. Isolated limb perfusion in primary and recurrent melanoma: Indications and results. Semin Surg Oncol. 1998;14:202–9.

    CAS  PubMed  Google Scholar 

  13. Klaase JM, Kroon BBR, Benckhuysen C et al. Results of regional isolation perfusion with cytostatics in patients with soft-tissue tumors of the extremities. Cancer. 1989;64: 616–21.

    CAS  PubMed  Google Scholar 

  14. Aggarwal BB, Kohr WJ, Hass PE et al. Human tumor necrosis factor: production, purification and characterization. Biol Chem. 1985;260:2345–54.

    CAS  Google Scholar 

  15. Bevilcqua MP, Pober JS, Majeau GR et al. Recombinant tumor necrosis factor induces coagulant activity in cultured human vasculature endothelium; characterization and comparison with actions of interleukin-1. Proc Natl Acad Sci USA. 1986;83:4533–7.

    Google Scholar 

  16. Alexander HR, Fraker DL, Bartlett DL. Isolated limb perfusion for malignant melanoma. Semin Surg Oncol. 1996;12:416–26.

    Article  PubMed  Google Scholar 

  17. Cheresh DA. Death to a blood vessel, death to a tumor. Nature Med. 1998;4:395–8.

    CAS  PubMed  Google Scholar 

  18. Ruegg C. Evidence for the involvement of endothelial cell integrin α/β3 in the disruption of the tumor vasculature induced by TNF and IFN-γ Nature Med. 1998;4:408–14.

    CAS  PubMed  Google Scholar 

  19. Regeness A, Muller M, Curschellas E et al. Antitumor effects of tumor necrosis factor in combination with chemotherapeutic agents. Int J Cancer. 1987;39:266–73.

    Google Scholar 

  20. Watanabe N, Niitso Y, Umeno N et al. Synergistic cytotoxic and antitumor effects of recombinant human tumor necrosis factor and hyperthermia. Cancer Res. 1988;48: 650–3.

    CAS  PubMed  Google Scholar 

  21. Vrouenraets BC, Klaase JM, Kroon BB et al. Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions. Arch Surg. 1995; 130:43–7.

    CAS  PubMed  Google Scholar 

  22. Klaase JM, Kroon BB, van Slooten GW et al. Relation between calculated melphalan peak concentrations and toxicity in regional isolated perfusion for melanoma. Reg Cancer Treat. 1992;4:309–12.

    Google Scholar 

  23. Gutman M, Inbar M, Shlush-Lev D et al. High dose tumor necrosis factor alpha and melphalan administered via isolated limb perfusion for advanced soft tissue sarcoma results in a >90% response rate and limb preservation. Cancer. 1997;79:1129–37.

    Article  CAS  PubMed  Google Scholar 

  24. Hoekstra HJ, Naujocks T, Schraffordt Koops Het et al. Continuous leakage monitoring during hyperthermic isolated regional perfusion of the lower limb: techniques and results. Reg Cancer Treat. 1992;4:301–4.

    Google Scholar 

  25. Gaynor JJ, Tan CC, Casper ES et al. Refinement of clinicopathologic staging for localized soft tissue sarcoma of the extremity: a study of 423 adults. J Clin Oncol. 1992; 10:1317–27.

    CAS  PubMed  Google Scholar 

  26. Lawrence W, Donegan WL, Natrajan N et al. Adult soft-tissue sarcomas; a pattern of care survey of the American College of Surgeons. Ann Surg. 1987;205:349–59.

    PubMed  Google Scholar 

  27. Eilber FR, Eckhardt JF, Rosen G et al. Neoadjuvant chemotherapy and radiotherapy in the multidisciplinary management of soft-tissue sarcomas of the extremity. Surg Oncol Clin N Am. 1993;2:611–20.

    Google Scholar 

  28. Krementz ET, Carter RD, Sutherland CM et al. Chemotherapy of sarcomas of the limbs by regional perfusion. Ann Surg. 1977;185:555–64

    CAS  PubMed  Google Scholar 

  29. Sijens PE, Eggermont AMM, Van Dijk P et al. 31P magnetic resonance spectroscopy as predictor for clinical response in human extremity sarcoma treated by single dose TNF-alpha and melphalan isolated limb perfusion. NMR Biomed. 1995;8:215–21.

    CAS  PubMed  Google Scholar 

  30. Nieweg OF, Prulm J, Hoekstra HY et al. Positron emission tomography with fluorine-18-fluorodeoxyglucose for the evaluation of therapeutic isolated regional limb perfusion in a patient with soft-tissue sarcoma. J Nucl Med. 1994; 35:90–2.

    CAS  PubMed  Google Scholar 

  31. Vaglini M, Belli F, Ammatuna M et al. Treatment of primary or relapsing limb cancer by isolation perfusion with high dosealpha-tumor necrosis factor gamma interferon and melphalan. Cancer. 1994;73:483–92.

    CAS  PubMed  Google Scholar 

  32. Lev D, Abu-Abid S, Kollander Y et al. Multifocal soft tissue sarcoma limb salavage following isolated limb perfusion with tumor necrosis factor and melphalan. J Surg Oncol. 1999;70:185–98.

    Google Scholar 

Download references

Authors
  1. Joseph M. Klausner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dina Lev-Chelouche
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Isaac Meller
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Moshe Inbar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mordechai Gutman
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Kluwer Academic Publishers

About this chapter

Cite this chapter

Klausner, J.M., Lev-Chelouche, D., Meller, I., Inbar, M., Gutman, M. (2004). Isolated Limb Perfusion in the Treatment of Advanced Soft-tissue Sarcomas. In: Musculoskeletal Cancer Surgery. Springer, Dordrecht. https://doi.org/10.1007/0-306-48407-2_4

Download citation

  • DOI: https://doi.org/10.1007/0-306-48407-2_4

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-0-7923-6394-1

  • Online ISBN: 978-0-306-48407-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation